BioCentury
ARTICLE | Clinical News

Royal DSM preclinical data

May 13, 2013 7:00 AM UTC

In mice, single doses of 1.7, 5 and 15 µg recombinant hemagglutinin (rHA) vaccine with or without adjuvant given 21 days before a lethal H1N1 viral challenge led to survival rates of 80-100%. Additionally, complete protection was achieved in all mice who received the vaccine on days 0 and 21 with or without adjuvant following a lethal H1N1 viral challenge 21 days following the second vaccination. Data were published in PloS ONE. The vaccine comprises an rHA protein derived from the A/Puerto Rico/8/34 strain of the H1N1 influenza virus expressed in Schizochytrium microbial algae. ...